Table 1.

Patient demographics and baseline disease characteristics

Demographic or characteristicCORAL (n = 257)LY.12 (n = 221)Total (N = 478)
Mean age (range), y 51 (19-66) 54 (25-71) 53 (19-71) 
Sex    
 Female 91 (35) 84 (38) 175 (37) 
 Male 166 (65) 137 (62) 303 (63) 
IPI score*    
 0 to 1 125 (50) 98 (44) 223 (47) 
 2 73 (29) 72 (33) 145 (31) 
 ≥3 52 (21) 51 (23) 103 (22) 
Disease stage    
 I 43 (17) 21 (10) 64 (13) 
 II 64 (25) 64 (29) 128 (27) 
 III 43 (17) 55 (25) 98 (21) 
 IV 105 (41) 81 (36) 186 (39) 
LDH > upper limit of normal 111 (44) 99 (45) 210 (44) 
Rituximab included in initial and salvage therapy 135 (53) 123 (56) 258 (54) 
Stage 150 (58) 136 (62) 285 (60) 
Prior radiotherapy 74 (29) 54 (24) 128 (27) 
B symptoms 48 (19) 58 (27) 106 (23) 
Response to first line therapy    
 CR, CRu, PR 233 (91) 184 (83) 417 (87) 
 PD, SD 24 (9) 37 (17) 61 (13) 
Demographic or characteristicCORAL (n = 257)LY.12 (n = 221)Total (N = 478)
Mean age (range), y 51 (19-66) 54 (25-71) 53 (19-71) 
Sex    
 Female 91 (35) 84 (38) 175 (37) 
 Male 166 (65) 137 (62) 303 (63) 
IPI score*    
 0 to 1 125 (50) 98 (44) 223 (47) 
 2 73 (29) 72 (33) 145 (31) 
 ≥3 52 (21) 51 (23) 103 (22) 
Disease stage    
 I 43 (17) 21 (10) 64 (13) 
 II 64 (25) 64 (29) 128 (27) 
 III 43 (17) 55 (25) 98 (21) 
 IV 105 (41) 81 (36) 186 (39) 
LDH > upper limit of normal 111 (44) 99 (45) 210 (44) 
Rituximab included in initial and salvage therapy 135 (53) 123 (56) 258 (54) 
Stage 150 (58) 136 (62) 285 (60) 
Prior radiotherapy 74 (29) 54 (24) 128 (27) 
B symptoms 48 (19) 58 (27) 106 (23) 
Response to first line therapy    
 CR, CRu, PR 233 (91) 184 (83) 417 (87) 
 PD, SD 24 (9) 37 (17) 61 (13) 

Values are n (%) unless otherwise indicated.

CR, complete remission; Cru, complete remission unconfirmed; LDH, lactate dehydrogenase; PD, progressive disease; PR, partial remission; SD, stable disease.

*

IPI was determined at time of salvage chemotherapy.

Close Modal

or Create an Account

Close Modal
Close Modal